nach oben

Journal of Cancer Research and Clinical Oncology

Erschienen in:

01.01.2012 | Original Paper

Adjuvant immunotherapy of C6 glioma in rats with pertussis toxin

verfasst von: Mario Orozco-Morales, Francisco-Javier Sánchez-García, Patricia Guevara-Salazar, Oscar Arrieta, Norma Y. Hernández-Pedro, Aurora Sánchez-García, Rodolfo Perez-Madrigal, Edgar Rangel-López, Benjamín Pineda, Julio Sotelo

Erschienen in: Journal of Cancer Research and Clinical Oncology | Ausgabe 1/2012

Einloggen, um Zugang zu erhalten

Abstract

Purpose

In spite of the recent advances in surgery and antitumor drugs, the brain tumors, like glioblastoma, have shown a poor prognosis. The aim of this study was to determine the effect of pertussis toxin (PTx) as immunomodulatory molecule on glial tumors induced by C6 glioma cells.

Methods

Given the pleiotropic effect of PTx on the immune system, we analyzed the effect of PTx on CD4+/CD25+/FoxP3+ (Treg) cells like as immunotherapeutic adjuvant. Thirty rats with a glial tumor of 1.5 cm in diameter were separated in two groups: the first group was treated with PTx and the second group was non-treated (controls). Tumoral volume was measured weekly; tumor, blood and spleen were taken for analysis of subpopulations of T cells, apoptotic index and cytokine contents, in both groups.

Results

We observed a significant decrease in tumor volume in the PTx group; this was associated with a decreased in the number of Treg cells, in both spleen and tumor. The percentage of apoptotic cells was increased as compared with that of controls. The production of proinflammatory cytokines was increased in mRNA for IL-6 as well as a small increase in the mRNA expression of perforin and granzime in tumors from rats treated with PTx. No changes were found in the mRNA expression of MCP-1 and MIP-1α.

Conclusion

These results suggest that PTx could be an immunotherapeutic adjuvant in the integral therapy against glial tumors.

Agarwal RK, Sun SH, Su SB, Chan CC, Caspi RR (2002) Pertussis toxin alters the innate and the adaptive immune responses in a pertussis-dependent model of autoimmunity. J Neuroimmunol 129:133–140PubMedCrossRef

Alt C, Laschinger M, Engelhardt B (2002) Functional expression of the lymphoid chemokines CCL19 (ELC) and CCL 21 (SLC) at the blood-brain barrier suggests their involvement in G-protein-dependent lymphocyte recruitment into the central nervous system during experimental autoimmune encephalomyelitis. Eur J Immunol 32:2133–2144PubMedCrossRef

Arrieta O, Guevara P, Reyes S, Ortiz A, Rembao D, Sotelo J (1998) Protamine inhibits angiogenesis and growth of C6 rat glioma; a synergistic effect when combined with carmustine. Eur J Cancer 34:2101–2106PubMedCrossRef

Backlund PS Jr, Meade BD, Manclark CR, Cantoni GL, Aksamit RR (1985) Pertussis toxin inhibition of chemotaxis and the ADP-ribosylation of a membrane protein in a human-mouse hybrid cell line. Proc Natl Acad Sci USA 82:2637–2641PubMedCrossRef

Barnett B, Kryczek I, Cheng P, Zou W, Curiel TJ (2005) Regulatory T cells in ovarian cancer: biology and therapeutic potential. Am J Reprod Immunol 54:369–377PubMedCrossRef

Benda P, Lightbody J, Sato G, Levine L, Sweet W (1968) Differentiated rat glial cell strain in tissue culture. Science 161:370–371PubMedCrossRef

Bruckener KE, el Baya A, Galla HJ, Schmidt MA (2003) Permeabilization in a cerebral endothelial barrier model by pertussis toxin involves the PKC effector pathway and is abolished by elevated levels of cAMP. J Cell Sci 116:1837–1846PubMedCrossRef

Buckner JC (2003) Factors influencing survival in high-grade gliomas. Semin Oncol 30:10–14PubMedCrossRef

Cassan C, Piaggio E, Zappulla JP, Mars LT, Couturier N, Bucciarelli F, Desbois S, Bauer J, Gonzalez-Dunia D, Liblau RS (2006) Pertussis toxin reduces the number of splenic Foxp3+ regulatory T cells. J Immunol 177:1552–1560PubMed

Chattopadhyay S, Chakraborty NG, Mukherji B (2005) Regulatory T cells and tumor immunity. Cancer Immunol Immunother 54:1153–1161PubMedCrossRef

Chen X, Winkler-Pickett RT, Carbonetti NH, Ortaldo JR, Oppenheim JJ, Howard OM (2006) Pertussis toxin as an adjuvant suppresses the number and function of CD4+CD25+ T regulatory cells. Eur J Immunol 36:671–680PubMedCrossRef

Chen X, Howard OM, Oppenheim JJ (2007) Pertussis toxin by inducing IL-6 promotes the generation of IL-17-producing CD4 cells. J Immunol 178:6123–6129PubMed

Curiel TJ, Coukos G, Zou L, Alvarez X, Cheng P, Mottram P, Evdemon-Hogan M, Conejo-Garcia JR, Zhang L, Burow M, Zhu Y, Wei S, Kryczek I, Daniel B, Gordon A, Myers L, Lackner A, Disis ML, Knutson KL, Chen L, Zou W (2004) Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med 10:942–949PubMedCrossRef

Cyster JG, Goodnow CC (1995) Pertussis toxin inhibits migration of B and T lymphocytes into splenic white pulp cords. J Exp Med 182:581–586PubMedCrossRef

Darabi K, Karulin AY, Boehm BO, Hofstetter HH, Fabry Z, LaManna JC, Chavez JC, Tary-Lehmann M, Lehmann PV (2004) The third signal in T cell-mediated autoimmune disease? J Immunol 173:92–99PubMed

Deorah S, Lynch CF, Sibenaller ZA, Ryken TC (2006) Trends in brain cancer incidence, survival in the United States: Surveillance, Epidemiology, End Results Program, 1973 to 2001. Neurosurg Focus 20:E1PubMedCrossRef

El Andaloussi A, Lesniak MS (2006) An increase in CD4+CD25+FOXP3+ regulatory T cells in tumor-infiltrating lymphocytes of human glioblastoma multiforme. Neuro Oncol 8:234–243PubMedCrossRef

El Andaloussi A, Lesniak MS (2007) CD4+CD25+FoxP3+ T-cell infiltration and heme oxygenase-1 expression correlate with tumor grade in human gliomas. J Neurooncol 83:145–152PubMedCrossRef

El Andaloussi A, Han Y, Lesniak MS (2006) Prolongation of survival following depletion of CD4+CD25+ regulatory T cells in mice with experimental brain tumors. J Neurosurg 105:430–437PubMedCrossRef

Fecci PE, Mitchell DA, Whitesides JF, Xie W, Friedman AH, Archer GE, Herndon JE 2nd, Bigner DD, Dranoff G, Sampson JH (2006) Increased regulatory T-cell fraction amidst a diminished CD4 compartment explains cellular immune defects in patients with malignant glioma. Cancer Res 66:3294–3302PubMedCrossRef

Garcia-Lora A, Algarra I, Garrido F (2003) MHC class I antigens, immune surveillance, and tumor immune escape. J Cell Physiol 195:346–355PubMedCrossRef

Golgher D, Jones E, Powrie F, Elliott T, Gallimore A (2002) Depletion of CD25+ regulatory cells uncovers immune responses to shared murine tumor rejection antigens. Eur J Immunol 32:3267–3275PubMedCrossRef

Guevara P, Sotelo J (1999) C6 rat glioma grown into the peritoneal cavity, a large source of tumoral cells for subcutaneous transplant of glioma. J Neurooncol 44:91–92PubMedCrossRef

Hart MN, Linthicum DS, Waldschmidt MM, Tassell SK, Schelper RL, Robinson RA (1987) Experimental autoimmune inflammatory myopathy. J Neuropathol Exp Neurol 46:511–521PubMedCrossRef

He J, Gurunathan S, Iwasaki A, Ash-Shaheed B, Kelsall BL (2000) Primary role for Gi protein signaling in the regulation of interleukin 12 production and the induction of T helper cell type 1 responses. J Exp Med 191:1605–1610PubMedCrossRef

Hofstetter HH, Shive CL, Forsthuber TG (2002) Pertussis toxin modulates the immune response to neuroantigens injected in incomplete Freund’s adjuvant: induction of Th1 cells and experimental autoimmune encephalomyelitis in the presence of high frequencies of Th2 cells. J Immunol 169:117–125PubMed

Hou W, Wu Y, Sun S, Shi M, Sun Y, Yang C, Pei G, Gu Y, Zhong C, Sun B (2003) Pertussis toxin enhances Th1 responses by stimulation of dendritic cells. J Immunol 170:1728–1736PubMed

Ichihara F, Kono K, Takahashi A, Kawaida H, Sugai H, Fujii H (2003) Increased populations of regulatory T cells in peripheral blood and tumor-infiltrating lymphocytes in patients with gastric and esophageal cancers. Clin Cancer Res 9:4404–4408PubMed

Jager D, Jager E, Knuth A (2001) Immune responses to tumour antigens: implications for antigen specific immunotherapy of cancer. J Clin Pathol 54:669–674PubMedCrossRef

Kohno S, Munoz JA, Williams TM, Teuscher C, Bernard CC, Tung KS (1983) Immunopathology of murine experimental allergic orchitis. J Immunol 130:2675–2682PubMed

Li M, Liu J, Zhang SZ, Zhou Y, Guo YW, Chen Q, Ke YQ, Jiang XD, Cai YQ (2011) Cellular immunologic response to primary cryoablation of C6 gliomas in rats. Technol Cancer Res Treat 10:95–100

Linehan DC, Goedegebuure PS (2005) CD25+CD4+ regulatory T-cells in cancer. Immunol Res 32:155–168PubMedCrossRef

Linthicum DS (1982) Development of acute autoimmune encephalomyelitis in mice: factors regulating the effector phase of the disease. Immunobiology 162:211–220PubMedCrossRef

Linthicum DS, Frelinger JA (1982) Acute autoimmune encephalomyelitis in mice. II. Susceptibility is controlled by the combination of H-2 and histamine sensitization genes. J Exp Med 156:31–40PubMedCrossRef

Liyanage UK, Moore TT, Joo HG, Tanaka Y, Herrmann V, Doherty G, Drebin JA, Strasberg SM, Eberlein TJ, Goedegebuure PS, Linehan DC (2002) Prevalence of regulatory T cells is increased in peripheral blood and tumor microenvironment of patients with pancreas or breast adenocarcinoma. J Immunol 169:2756–2761PubMed

Lopez-Gonzalez MA, Sotelo J (2000) Brain tumors in Mexico: characteristics and prognosis of glioblastoma. Surg Neurol 53:157–162PubMedCrossRef

Mascart F, Verscheure V, Malfroot A, Hainaut M, Pierard D, Temerman S, Peltier A, Debrie AS, Levy J, Del Giudice G, Locht C (2003) Bordetella pertussis infection in 2-month-old infants promotes type 1 T cell responses. J Immunol 170:1504–1509PubMed

Mielcarek N, Hornquist EH, Johansson BR, Locht C, Abraham SN, Holmgren J (2001) Interaction of Bordetella pertussis with mast cells, modulation of cytokine secretion by pertussis toxin. Cell Microbiol 3:181–188PubMedCrossRef

Munoz JJ, Bernard CC, Mackay IR (1984) Elicitation of experimental allergic encephalomyelitis (EAE) in mice with the aid of pertussigen. Cell Immunol 83:92–100PubMedCrossRef

Nencioni L, Pizza MG, Volpini G, De Magistris MT, Giovannoni F, Rappuoli R (1991) Properties of the B oligomer of pertussis toxin. Infect Immun 59:4732–4734PubMed

Onizuka S, Tawara I, Shimizu J, Sakaguchi S, Fujita T, Nakayama E (1999) Tumor rejection by in vivo administration of anti-CD25 (interleukin-2 receptor alpha) monoclonal antibody. Cancer Res 59:3128–3133PubMed

Papaspyridonos M, McNeill E, de Bono JP, Smith A, Burnand KG, Channon KM, Greaves DR (2008) Galectin-3 is an amplifier of inflammation in atherosclerotic plaque progression through macrophage activation and monocyte chemoattraction. Arterioscler Thromb Vasc Biol 28:433–440PubMedCrossRef

Pineda B, Estrada-Parra S, Pedraza-Medina B, Rodriguez-Ropon A, Perez R, Arrieta O (2005) Interstitial transfer factor as adjuvant immunotherapy for experimental glioma. J Exp Clin Cancer Res 24:575–583PubMed

Ryan M, McCarthy L, Rappuoli R, Mahon BP, Mills KH (1998) Pertussis toxin potentiates Th1 and Th2 responses to co-injected antigen: adjuvant action is associated with enhanced regulatory cytokine production and expression of the co-stimulatory molecules B7–1, B7–2 and CD28. Int Immunol 10:651–662PubMedCrossRef

Shimizu J, Yamazaki S, Sakaguchi S (1999) Induction of tumor immunity by removing CD25+CD4+ T cells: a common basis between tumor immunity and autoimmunity. J Immunol 163:5211–5218PubMed

Shive CL, Hofstetter H, Arredondo L, Shaw C, Forsthuber TG (2000) The enhanced antigen-specific production of cytokines induced by pertussis toxin is due to clonal expansion of T cells and not to altered effector functions of long-term memory cells. Eur J Immunol 30:2422–2431PubMedCrossRef

Strojnik T, Kavalar R, Zajc I, Diamandis EP, Oikonomopoulou K, Lah TT (2009) Prognostic impact of CD68 and kallikrein 6 in human glioma. Anticancer Res 29:3269–3279PubMed

Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn U, Curschmann J, Janzer RC, Ludwin SK, Gorlia T, Allgeier A, Lacombe D, Cairncross JG, Eisenhauer E, Mirimanoff RO (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352:987–996PubMedCrossRef

Tomayko MM, Reynolds CP (1989) Determination of subcutaneous tumor size in athymic (nude) mice. Cancer Chemother Pharmacol 24:148–154

Tonon S, Goriely S, Aksoy E, Pradier O, Del Giudice G, Trannoy E, Willems F, Goldman M, De Wit D (2002) Bordetella pertussis toxin induces the release of inflammatory cytokines and dendritic cell activation in whole blood: impaired responses in human newborns. Eur J Immunol 32:3118–3125PubMedCrossRef

Velasquez-Perez L, Jimenez-Marcial ME (2003) Clinical-histopathologic concordance of tumors of the nervous system at the Manuel Velasco Suarez National Institute of Neurology and Neurosurgery in Mexico City. Arch Pathol Lab Med 127:187–192PubMed

Woo EY, Chu CS, Goletz TJ, Schlienger K, Yeh H, Coukos G, Rubin SC, Kaiser LR, June CH (2001) Regulatory CD4(+)CD25(+) T cells in tumors from patients with early-stage non-small cell lung cancer and late-stage ovarian cancer. Cancer Res 61:4766–4772PubMed

Zhu X, Lu C, Xiao B, Qiao J, Sun Y (2005) An experimental study of dendritic cells mediated immunotherapy against intracranial gliomas in rats. J Neurooncol 74:9–17

Titel: Adjuvant immunotherapy of C6 glioma in rats with pertussis toxin
verfasst von: Mario Orozco-Morales
Francisco-Javier Sánchez-García
Patricia Guevara-Salazar
Oscar Arrieta
Norma Y. Hernández-Pedro
Aurora Sánchez-García
Rodolfo Perez-Madrigal
Edgar Rangel-López
Benjamín Pineda
Julio Sotelo
Publikationsdatum: 01.01.2012
Verlag: Springer-Verlag
Erschienen in: Journal of Cancer Research and Clinical Oncology / Ausgabe 1/2012
Print ISSN: 0171-5216
Elektronische ISSN: 1432-1335
DOI: https://doi.org/10.1007/s00432-011-1069-y

Neu im Fachgebiet Onkologie

24.04.2024 | DGIM 2024 | Nachrichten

Springer Medizin

Adjuvant immunotherapy of C6 glioma in rats with pertussis toxin

Abstract

Purpose

Methods

Results

Conclusion

Neu im Fachgebiet Onkologie

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Krebspatienten impfen: Was? Wen? Und wann nicht?

Müde im Alter? Auch an die Nebenniere denken

Update Onkologie

Springer Medizin

Abstract

Purpose

Methods

Results

Conclusion

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2012

First-line panitumumab plus irinotecan/5-fluorouracil/leucovorin treatment in patients with metastatic colorectal cancer

Receptor for advanced glycation end products (RAGE) partially mediates HMGB1-ERKs activation in clear cell renal cell carcinoma

The microRNA-processing enzymes: Drosha and Dicer can predict prognosis of nasopharyngeal carcinoma

Expression of coagulation factors and their receptors in tumor tissue and coagulation factor upregulation in peripheral blood of patients with cerebral carcinoma metastases

Calcium-binding protein S100P and cancer: mechanisms and clinical relevance

The pattern of lymph node metastasis and the suitability of 7th UICC N stage in predicting prognosis of remnant gastric cancer

Neu im Fachgebiet Onkologie

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Krebspatienten impfen: Was? Wen? Und wann nicht?

Müde im Alter? Auch an die Nebenniere denken

Update Onkologie